Jim Simons
NKTR icon

Jim Simons’s Nektar Therapeutics NKTR Stock Holding History

Jim Simons’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Sell
41,781
-131,100
-76% -$7.46M ﹤0.01% 1661
2025
Q4 		$7.31M Sell
172,881
-105,660
-38% -$5.91M 0.01% 1081
2025
Q3 		$15.8M Buy
278,541
+31,481
+13% +$1.04M 0.02% 849
2025
Q2 		$6.38M Sell
247,060
-66,392
-21% -$745K 0.01% 1363
2025
Q1 		$3.2M Buy
313,452
+52,733
+20% +$689K ﹤0.01% 1707
2024
Q4 		$3.64M Buy
260,719
+38,877
+18% +$686K 0.01% 1646
2024
Q3 		$4.33M Buy
221,842
+920
+0.4% +$17.5K 0.01% 1532
2024
Q2 		$4.11M Sell
220,922
-87,123
-28% -$1.84M 0.01% 1434
2024
Q1 		$4.32M Sell
308,045
-46,987
-13% -$492K 0.01% 1506
2023
Q4 		$3.01M Buy
355,032
+121,253
+52% +$918K ﹤0.01% 1690
2023
Q3 		$2.09M Sell
233,779
-39,000
-14% -$375K ﹤0.01% 1833
2023
Q2 		$2.35M Buy
272,779
+72,533
+36% +$773K ﹤0.01% 1890
2023
Q1 		$2.11M Buy
200,246
+192,439
+2,465% +$5.82M ﹤0.01% 1992
2022
Q4 		$265K Buy
+7,807
New +$378K ﹤0.01% 3282
2019
Q3 		– Sell
-21,803
Closed -$11.6M – 3610
2019
Q2 		$11.6M Buy
21,803
+8,106
+59% +$4.06M 0.01% 1302
2019
Q1 		$6.9M Sell
13,697
-13,100
-49% -$7.76M 0.01% 1604
2018
Q4 		$13.2M Buy
26,797
+22,207
+484% +$13.4M 0.01% 1149
2018
Q3 		$4.2M Buy
4,590
+2,667
+139% +$2.28M ﹤0.01% 1914
2018
Q2 		$1.41M Buy
+1,923
New +$2.22M ﹤0.01% 2450
2018
Q1 		– Sell
-6,123
Closed -$5.49M – 3504
2017
Q4 		$5.49M Buy
+6,123
New +$3.62M 0.01% 1747
2015
Q2 		– Sell
-37,870
Closed -$6.25M – 3315
2015
Q1 		$6.25M Buy
37,870
+9,060
+31% +$1.86M 0.01% 1222
2014
Q4 		$6.7M Buy
+28,810
New +$6.16M 0.02% 1106

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jim Simons's NKTR Position: Q1 2026 in Review

Jim Simons reduced its Nektar Therapeutics (NKTR) stake by 76% in Q1 2026, selling an estimated $7.46M and leaving 41,781 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

Jim Simons first reported a position in NKTR in Q4 2014 and has held it in 22 quarters since. The position peaked at $15.8M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Jim Simons held 41,781 shares of Nektar Therapeutics worth $3.01M as of Q1 2026.
  • Jim Simons sold 131,100 Nektar Therapeutics shares in Q1 2026, an estimated $7.46M.
  • Nektar Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1661 holding.
  • Jim Simons first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 22 quarters since.
  • Jim Simons's Nektar Therapeutics position peaked at $15.8M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.